Newby DE - Search Results

1

Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans.

Gudmundsdóttir IJ, Megson IL, Kell JS, Ludlam CA, Fox KA, Webb DJ, Newby DE. Gudmundsdóttir IJ, et al. Among authors: newby de. Circulation. 2006 Oct 10;114(15):1625-32. doi: 10.1161/CIRCULATIONAHA.106.638478. Epub 2006 Oct 2. Circulation. 2006. PMID: 17015787 Clinical Trial.

2

Advances in clinical pharmacology and therapeutics: endothelin.

Newby DE, Webb DJ. Newby DE, et al. Br J Hosp Med. 1996 Oct 2-15;56(7):360-4. Br J Hosp Med. 1996. PMID: 8899226 Review.

3

The endothelin system in cardiovascular disease.

Newby DE, Webb DJ. Newby DE, et al. BMJ. 1997 Feb 22;314(7080):531-2. doi: 10.1136/bmj.314.7080.531. BMJ. 1997. PMID: 9055700 Free PMC article. No abstract available.

4

Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide.

Newby DE, Boon NA, Webb DJ. Newby DE, et al. Clin Sci (Lond). 1997 Feb;92(2):133-8. doi: 10.1042/cs0920133. Clin Sci (Lond). 1997. PMID: 9059313 Clinical Trial.

5

Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability.

Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ. Newby DE, et al. Br J Clin Pharmacol. 1997 May;43(5):493-9. doi: 10.1046/j.1365-2125.1997.00583.x. Br J Clin Pharmacol. 1997. PMID: 9159564 Free PMC article. Clinical Trial.

6

Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans.

Masumori S, Newby DE, Strachan FE, Boon NA, Webb DJ. Masumori S, et al. Among authors: newby de. Clin Pharmacol Ther. 1997 Sep;62(3):327-33. doi: 10.1016/S0009-9236(97)90036-9. Clin Pharmacol Ther. 1997. PMID: 9333109 Clinical Trial.

7

The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction.

Ferro CJ, Haynes WG, Johnston NR, Lomax CC, Newby DE, Webb DJ. Ferro CJ, et al. Among authors: newby de. Br J Clin Pharmacol. 1997 Oct;44(4):377-83. doi: 10.1046/j.1365-2125.1997.00595.x. Br J Clin Pharmacol. 1997. PMID: 9354313 Free PMC article. Clinical Trial.

8

An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium.

Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. Newby DE, et al. Thromb Haemost. 1997 Oct;78(4):1242-8. Thromb Haemost. 1997. PMID: 9364992

9

Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man.

Newby DE, Masumori S, Johnston NR, Boon NA, Webb DJ. Newby DE, et al. Cardiovasc Res. 1997 Nov;36(2):268-75. doi: 10.1016/s0008-6363(97)00171-5. Cardiovasc Res. 1997. PMID: 9463638 Clinical Trial.

10

Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade.

Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Verhaar MC, et al. Among authors: newby de. Circulation. 1998 Mar 3;97(8):752-6. doi: 10.1161/01.cir.97.8.752. Circulation. 1998. PMID: 9498538

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

869 results

Search Page

Filters